Home › Research › Treatments
Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia
Mario Emiliano Ricciardi, Iván Burgueño‐García, Elizabeth Valeriano-Lorenzo, María Ascensión Zea‐Sevilla, Meritxell Valenti, Belén Frades, Isabel López Torres, Marta Anton‐Moreno et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Abstract Background Cerebral amyloid angiopathy (CAA) is closely related and coexists with Alzheimer's disease (AD) and is considered a major risk factor for the development of ARIA in patients receiving anti‐amyloid therapies. Brain magnetic resonance imaging (MRI) is the standard method for assessing the presence of CAA, but its performance has been poorly studied in this population. Our objective was to evaluate the diagnostic performance of the Boston criteria version 2.0 for the diagnosis of CAA in a cohort of individuals diagnosed with advanced AD with neuropathological confirmation. Method We included 63 individuals from the VARS cohort of the Alzheimer´s Centre Reina Sofía ‐ CIEN Foundation, a clinicopathological cohort of dementia patients, with no history of intracranial haemorrhage. All had undergone at least one antemortem MRI with T1, T2, T2 Flair and GRE sequences, and a brain autopsy with evaluation of CAA using the modified Vonsattel scale. The performance of the Boston v2.0 criteria was evaluated by comparison with neuropathologically verified CAA. Result The mean age at MRI was 84.7 ± 7 years and the median time from MRI to death was 2.5 years [0.6‐4.5]. 54 were women (86%). 46 (73%) individuals had neuropathologically confirmed CAA (i.e. moderate or severe CAA). 38 (60,3%) subjects did not meet the Boston v2.0 criteria and 45% of them had moderate or severe CAA. The sensitivity and specificity of the Boston v2.0 criteria were 40.8% [95% CI 27%‐55.8%] and 64.2% [95% CI 35.1%‐87.2%] respectively for the diagnosis of probable CAA (AUC 0.52), and 83.7% [95% CI 70.3%‐92.7%] and 35.7% [95% CI 12.8%‐64.9%] for the diagnosis of possible CAA (AUC 0.51). Conclusion The Boston v2.0 criteria have low accuracy in patients with AD dementia. New biomarkers are needed to improve the diagnosis of CAA in this population in order to improve the safety of treatment with anti‐amyloid drugs.
What this study adds
Evidence grade: Moderate
The record lists 63 participants. In 63 autopsy-confirmed dementia cases, 60.3% did not meet the Boston v2.0 criteria for cerebral amyloid angiopathy, and 45% of those had moderate or severe CAA. Reported effect size: 40.8%; 55.8%; 64.2%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ricciardi, M. E., Burgueño‐García, I., Valeriano-Lorenzo, E., Zea‐Sevilla, M. A., Valenti, M., Frades, B., et al. (2025). Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_105538
Vancouver
Ricciardi ME, Burgueño‐García I, Valeriano-Lorenzo E, Zea‐Sevilla MA, Valenti M, Frades B, et al. Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_105538.
BibTeX
@article{ricciardi2025-7cc0ff47,
author = {Ricciardi, Mario Emiliano and Burgueño‐García, Iván and Valeriano-Lorenzo, Elizabeth and Zea‐Sevilla, María Ascensión and Valenti, Meritxell and Frades, Belén and Torres, Isabel López and Anton‐Moreno, Marta and others},
title = {{Neuropathological evaluation of the Boston Criteria v2.0 for cerebral amyloid angiopathy in Alzheimer's disease dementia}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_105538},
url = {https://doi.org/10.1002/alz70856_105538}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Result The mean age at MRI was 84.7 ± 7 years and the median time from MRI to death was 2.5 years [0.6‐4.5]. 54 were women (86%). 46 (73%) individuals had neuropathologically confirmed CAA (i.e. moderate or severe CAA). 38 (60,3%) subjects did not meet the Boston v2.0 criteria and 45% of them had moderate or severe CAA.
Why it matters
In 63 autopsy-confirmed dementia cases, 60.3% did not meet the Boston v2.0 criteria for cerebral amyloid angiopathy, and 45% of those had moderate or severe CAA. This indicates the MRI-based criteria missed CAA in many patients, which matters for assessing ARIA risk, but the study tests diagnosis, not treatment or cure.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants63
- Effect size40.8%; 55.8%; 64.2%
- Evidence strengthModerate
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 36 of the 96 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 63 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Pascual Sanchez‐Juan holds only 4 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Instituto de Salud Carlos III: institution h-index 649 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Points | 36 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 36 of the 96 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “machine”
834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.